Drugs / 124I-Humanized 3F8
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| — | NCT02307630 | Nov 2014 → Nov 2026 expected | melanoma, neuroblastoma, sarcoma | Memorial Sloan Kettering Cancer Center | Active not recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 124I-Humanized 3F8 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02307630 ↗ |
| Known as | 124I-hu3F8 | “Blood will be drawn where feasible at multiple time points: approximately 0h, 0.5h, 1h, 2h, 4-8h, 24h, 48h, 96h and 120h-144h after injection of 124I-hu3F8 and radioactivity...” NCT02307630 ↗ |
| Route | Intravenous | “124I-hu3F8 at a dose of 3mCi/m2 (with a maximum dose of 5mCi) will be injected IV.” NCT02307630 ↗ |